• Forget CBA shares! Buy these ASX dividend shares instead for passive income

    A golden egg with dividend cash flying out of it

    Commonwealth Bank of Australia (ASX: CBA) is a powerful ASX dividend share with an impressive market share and a proud record of paying pleasing passive income to shareholders.

    However, CBA is not one of the businesses I’d buy for dividends, as impressive as the ASX bank share has been.

    FY26 saw the business hike its annual dividend per share by 4% to $5.05. At the time of writing, that translates into a grossed-up dividend yield of 4.7%, including franking credits.

    For me, there are other ASX dividend shares that offer a more compelling dividend yield and/or significantly more dividend growth potential. The following two stocks are much more appealing to me.

    L1 Long Short Fund Ltd (ASX: LSF)

    This business is a listed investment company (LIC), which means it invests in other shares/assets on behalf of shareholders. Having that diversification within a single investment is appealing compared to CBA, which is just one business and has a significant focus on providing home loans in Australia (an area of slow growth at best, right now).

    L1 generally likes to look at industries and specific businesses that don’t get as much investor attention and don’t trade on high price/earnings (P/E) ratios. The investment team have delivered significant success in industries like materials, industrials and communication services.

    Buying (and selling) materials shares at the right times can be very effective as investments because of how cyclical they can be.

    At the end of August 2026, the ASX dividend share’s portfolio registered an average net return of 17.1% per year over the prior five years, which is strong enough to deliver both capital growth and good dividends.

    In FY26, the LIC grew its annual payout by 14.5% – a much stronger growth rate than CBA.

    I expect the next four quarterly dividends from L1 Long Short Fund will come to at least 16.2 cents per share, which would be a grossed-up dividend yield of 4.8%, including franking credits.

    WCM Quality Global Growth Fund – Active ETF (ASX: WCMQ)

    The other ASX dividend share I want to highlight is this exchange-traded fund (ETF) offering from WCM.

    WCM is a fund manager based in Laguna Beach, California. That’s a deliberate choice to be so far away from the noise of Wall Street in New York.

    There are two key criteria for WCM to consider a company for this portfolio. It must have a growing competitive advantage (expanding economic moat) and a corporate culture that supports the expansion of the economic moat.

    The fund manager believes that the direction of the economic moat is more important than the absolute width or size. Therefore, seeing a rising return on invested capital (ROIC) – one of the main ways it measures that improvement – is more important than a large but static or declining economic moat.

    Additionally, WCM has team members solely dedicated to analysing the corporate culture of a business.

    Since the WCMQ ETF’s inception in August 2018, its portfolio has returned an average of 14.9% (net), compared to a 12.8% return per year for the global share market.

    The ASX dividend share aims to provide a minimum annualised cash dividend yield of 5%. That’s a stronger starting yield than CBA shares and I expect the distribution can grow at a faster pace over the long-term by focusing on high-quality shares.

    The post Forget CBA shares! Buy these ASX dividend shares instead for passive income appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Commonwealth Bank Of Australia right now?

    Before you buy Commonwealth Bank Of Australia shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Commonwealth Bank Of Australia wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Tristan Harrison has positions in L1 Long Short Fund and Wcm Quality Global Growth Fund. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • Buy, hold, sell: Domino’s Pizza, Telix Pharmaceuticals, Westfarmers shares

    A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, and holding a mobile phone in his other hand.

    The S&P/ASX 200 Index (ASX: XJO) has fallen further this week as investor sentiment continues to deteriorate.

    Ongoing conflict between the US and Iran is driving fresh concerns about restricted oil supply and inflation, and the renewed fears about further interest rate hikes are spooking investors.

    Let’s find out how the shift in sentiment is affecting major ASX 200 shares like Domino’s Pizza Enterprises Ltd (ASX: DMP), Telix Pharmaceuticals Ltd (ASX: TLX), and Wesfarmers Ltd (ASX: WES), and what brokers tip next.

    Buy Telix Pharmaceuticals shares

    Telix shares have rocketed over 10% higher in Tuesday afternoon trade to $17.99 apiece. Today’s increase means the shares are now up 58% year to date.

    Today’s increase comes on the back of yesterday’s news that its brain cancer imaging drug, Pixclara, has received approval from the US FDA. This makes it the first FET-PET imaging drug cleared for use in glioma and expands Telix’s precision medicine portfolio.

    Telix says Pixclara is already the subject of a Phase 3 trial for diagnosis in additional brain conditions, with potential expansion to brain metastases. 

    The company said it plans to target market leadership in both imaging and treatment for several high-need cancers.

    Telix’s broader pipeline includes late-stage assets in prostate, kidney, and glioblastoma cancers, with a focus on bringing further precision medicine products to both existing and new markets worldwide.

    Investors were clearly thrilled with the news, and many are rushing to snap up the shares.

    Analysts are very bullish on the outlook for the stock, too. Market Index data shows the majority of brokers have a buy rating on the shares, and even after today’s share price spike, the $24.68 average target price implies there is potential for about 37% upside ahead.

    Hold Domino’s Pizza shares

    Domino’s Pizza shares have climbed higher on Tuesday afternoon, up around 1% to $19.14 a piece at the time of writing. The shares are still down 12% year to date.

    It’s been a volatile month for the pizza operator. Its share price fell around 6% after the food operator announced its FY26 results, including a 11.2% decrease in revenue, and a statutory NPAT loss of $134.2 million. It also announced $255.7 million in non-cash write-downs and impairments.

    Domino’s underlying NPAT was up 4% for the 12-month period, and in line with guidance, but EBITDA fell 6.1%. The company also cut its total FY26 dividend by 25.3% to 57.5 cents.

    Going forward, Domino’s said it is planning to return to profitable growth in FY27 after a period of resetting its store network and business model. 

    But it looks like the experts are on the fence about whether this growth can come to fruition. Market Index data shows the majority of brokers have a hold rating on the ASX shares. The $20.10 average target price implies an upside of around 5% at the time of writing.

    Sell Wesfarmers shares

    Wesfarmers shares are in the red at the time of writing, down around 0.5% to $72.42 each. The shares have crashed by around 22% since late July and are now down 11% for the year to date.

    The shares were pushed lower in August amid broad pressure on consumer and retail stocks, as well as concerns about inflation and interest rate increases.

    The sell-off also picked up pace after the conglomerate posted its FY26 results in late August.

    The company reported a 3.4% increase in revenue to $47.3 million and a 7.3% increase in EBIT. But statutory NPAT fell 1.8% to $2.8 million, including significant items, or was up 8.3% excluding them. 

    Going forward, Wesfarmers said it expects higher capital expenditure in FY27, of $1.3 billion to $1.5 billion. 

    But investors were spooked, potentially because, although the result was robust, it raises questions about how the business can continue to grow in a weakening market.

    Brokers are concerned, too. Market Index data shows the majority now have a strong sell rating on Wesfarmers shares. After the latest price crash, the $77 average target price implies around a 6% upside at the time of writing.

    The post Buy, hold, sell: Domino’s Pizza, Telix Pharmaceuticals, Westfarmers shares appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Telix Pharmaceuticals right now?

    Before you buy Telix Pharmaceuticals shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Telix Pharmaceuticals wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Domino’s Pizza Enterprises, Telix Pharmaceuticals, and Wesfarmers. The Motley Fool Australia has recommended Domino’s Pizza Enterprises, Telix Pharmaceuticals, and Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

  • SpaceX shares are flying. Here’s the price I’d wait for

    A rocket blasts off into space with planet behind it.

    SpaceX has been one of the highest-profile listings of 2026.

    But excitement and a good entry price are not always the same thing.

    Space Exploration Technologies Corp (NASDAQ: SPCX) shares closed at US$148.15 on Monday.

    That’s above the US$135 IPO price, although the stock has already been on a wild ride since listing in June.

    It briefly traded as high as US$225.64 just days after its debut.

    Investors who chased the early surge are already sitting on a sizeable loss.

    And while the 34% pullback makes SpaceX look cheaper, that doesn’t necessarily mean it’s good value.

    Yes, I would love to own SpaceX shares at some point.

    I just wouldn’t buy them around current levels.

    Why I want to own SpaceX

    There is a lot I like about the business.

    SpaceX has built a position that would be extremely difficult for another company to copy.

    Its launch business is already enormous, and Starlink continues to add customers.

    Starship could also dramatically reduce the cost of putting satellites and other payloads into orbit if the program works as planned.

    The growth numbers are pretty impressive, too.

    Second-quarter revenue jumped 92% to US$7.8 billion, while adjusted EBITDA rose 191% to US$3.5 billion.

    Starlink now has around 12 million subscribers, and SpaceX is also spending heavily on AI infrastructure alongside its space and connectivity businesses.

    Evidently, this will give the company several ways to grow over the next decade.

    So what’s stopping me?

    The price.

    At around US$148 per share, SpaceX has a market cap at roughly US$2 trillion.

    That’s a huge valuation, especially for a company that still reported a US$541 million net loss in the second quarter.

    It’s spending heavily as well.

    Capital expenditure reached US$18.4 billion during the quarter, with US$15.8 billion going towards AI infrastructure.

    Of course, SpaceX could eventually grow into that valuation.

    Interestingly, Wall Street thinks there’s more upside, with the average analyst price target sitting around US$227.

    But at the current price, I think investors are already paying for a lot of future growth.

    Where would I buy?

    For me, things would get much more interesting below US$90.

    That would mean a fall of roughly 39% from yesterday’s closing price and put the shares well below their US$135 IPO price.

    Would SpaceX suddenly be cheap at US$90? Probably not.

    But I’d be much more comfortable starting a position around that level.

    At that price, I’d have a lot more room for things to go wrong.

    SpaceX is a company I genuinely want in my portfolio.

    I’m just happy to miss some upside if the alternative is paying too much.

    The post SpaceX shares are flying. Here’s the price I’d wait for appeared first on The Motley Fool Australia.

    Should you invest $1,000 in Space Exploration Technologies right now?

    Before you buy Space Exploration Technologies shares, consider this:

    Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Space Exploration Technologies wasn’t one of them.

    The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    And right now, Scott thinks there are 5 stocks that may be better buys…

    * Returns as of 1 August 2026

    .custom-cta-button p {
    margin-bottom: 0 !important;
    }

    More reading

    Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Sorry, but nothing was found. Please try a search with different keywords.